1. Home
  2. NVAX vs AFYA Comparison

NVAX vs AFYA Comparison

Compare NVAX & AFYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVAX
  • AFYA
  • Stock Information
  • Founded
  • NVAX 1987
  • AFYA 1999
  • Country
  • NVAX United States
  • AFYA Brazil
  • Employees
  • NVAX N/A
  • AFYA N/A
  • Industry
  • NVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • AFYA Other Consumer Services
  • Sector
  • NVAX Health Care
  • AFYA Real Estate
  • Exchange
  • NVAX Nasdaq
  • AFYA Nasdaq
  • Market Cap
  • NVAX 1.3B
  • AFYA 1.6B
  • IPO Year
  • NVAX 1995
  • AFYA 2019
  • Fundamental
  • Price
  • NVAX $7.98
  • AFYA $15.54
  • Analyst Decision
  • NVAX Buy
  • AFYA Hold
  • Analyst Count
  • NVAX 7
  • AFYA 5
  • Target Price
  • NVAX $14.29
  • AFYA $18.10
  • AVG Volume (30 Days)
  • NVAX 7.2M
  • AFYA 86.8K
  • Earning Date
  • NVAX 11-11-2025
  • AFYA 08-13-2025
  • Dividend Yield
  • NVAX N/A
  • AFYA 1.49%
  • EPS Growth
  • NVAX N/A
  • AFYA 20.40
  • EPS
  • NVAX 2.54
  • AFYA 1.36
  • Revenue
  • NVAX $1,078,718,000.00
  • AFYA $650,778,153.00
  • Revenue This Year
  • NVAX $61.69
  • AFYA $15.06
  • Revenue Next Year
  • NVAX N/A
  • AFYA $8.36
  • P/E Ratio
  • NVAX $3.25
  • AFYA $11.18
  • Revenue Growth
  • NVAX 9.22
  • AFYA 15.60
  • 52 Week Low
  • NVAX $5.01
  • AFYA $13.47
  • 52 Week High
  • NVAX $15.22
  • AFYA $19.90
  • Technical
  • Relative Strength Index (RSI)
  • NVAX 51.06
  • AFYA 56.39
  • Support Level
  • NVAX $7.63
  • AFYA $14.90
  • Resistance Level
  • NVAX $8.31
  • AFYA $15.75
  • Average True Range (ATR)
  • NVAX 0.35
  • AFYA 0.39
  • MACD
  • NVAX -0.00
  • AFYA 0.08
  • Stochastic Oscillator
  • NVAX 65.20
  • AFYA 46.01

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

About AFYA Afya Limited

Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergrad provides educational services through undergraduate courses related to medical school, undergraduate health science and other ex-health undergraduate programs, Continuing Education provides medical education, specialization and graduate courses in medicine, delivered through digital and in-person content; and Medical practice solution provides clinical decision, clinical management and doctor-patient relationships for physicians and provide access, demand and efficiency for the healthcare players.

Share on Social Networks: